Threes, you are essentially correct. Peregrine does not have the ability to raise any more drug development money at reasonable cost, especially in view of the de-listing, reverse split box they are in.
Partnering would permit Bavi-antiPS development, if the partner will carry the bulk of the cost.
Business as usual is an insult to shareholders. If Peregrine doesn't communicate with us, taking our beating now is better than taking a complete loss later IMO.
GLTA, Paul
News 
Market Data 
Discover 
